Ascendiant Capital Markets Forecasts Strong Price Appreciation for Pro-Dex (NASDAQ:PDEX) Stock

Pro-Dex (NASDAQ:PDEX – Get Free Report) had its target price lifted by equities researchers at Ascendiant Capital Markets from $74.00 to $80.00 in a report released on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Ascendiant Capital Markets‘s target price would suggest a potential upside of 29.18% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on PDEX. Zacks Research downgraded shares of Pro-Dex from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 9th. Weiss Ratings upgraded shares of Pro-Dex from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, November 10th. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $80.00.

View Our Latest Analysis on PDEX

Pro-Dex Stock Down 4.0%

NASDAQ PDEX opened at $61.93 on Monday. Pro-Dex has a twelve month low of $28.81 and a twelve month high of $77.00. The stock has a market cap of $198.18 million, a PE ratio of 17.67 and a beta of 0.12. The firm has a 50-day simple moving average of $64.77 and a 200 day simple moving average of $57.91. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.49 and a current ratio of 4.19.

Pro-Dex (NASDAQ:PDEX – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $20.56 million for the quarter, compared to analyst estimates of $20.40 million. Pro-Dex had a return on equity of 26.18% and a net margin of 15.12%. On average, research analysts forecast that Pro-Dex will post 3.09 EPS for the current year.

Insider Activity

In other Pro-Dex news, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of the company’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $60.58, for a total transaction of $1,165,256.30. Following the sale, the chief executive officer directly owned 79,993 shares of the company’s stock, valued at approximately $4,845,975.94. This represents a 19.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Alisha Charlton sold 2,300 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total transaction of $140,990.00. Following the sale, the chief financial officer directly owned 21,870 shares in the company, valued at $1,340,631. This represents a 9.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 22,300 shares of company stock valued at $1,351,657 over the last three months. 48.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC raised its position in Pro-Dex by 7,790.1% in the 3rd quarter. Global Retirement Partners LLC now owns 78,901 shares of the medical instruments supplier’s stock valued at $5,444,000 after purchasing an additional 77,901 shares during the last quarter. Punch & Associates Investment Management Inc. boosted its stake in Pro-Dex by 2.9% in the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock worth $3,032,000 after purchasing an additional 1,735 shares in the last quarter. Pekin Hardy Strauss Inc. boosted its stake in Pro-Dex by 38.2% in the third quarter. Pekin Hardy Strauss Inc. now owns 22,800 shares of the medical instruments supplier’s stock worth $1,573,000 after purchasing an additional 6,300 shares in the last quarter. Apriem Advisors bought a new stake in shares of Pro-Dex during the third quarter worth $1,385,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Pro-Dex by 6.6% during the third quarter. Goldman Sachs Group Inc. now owns 19,945 shares of the medical instruments supplier’s stock worth $1,376,000 after purchasing an additional 1,234 shares during the last quarter. 15.28% of the stock is owned by institutional investors and hedge funds.

About Pro-Dex

(Get Free Report)

Pro-Dex, Inc. designs, develops and manufactures powered surgical instruments and related accessories, with a focus on devices used in orthopedic procedures. Its products include surgical handpieces and drivers, along with the components and systems that support their operation. The company also provides engineering, product development and manufacturing services to medical device companies. Its work can span the product lifecycle, from design and prototyping to production and servicing. Founded in 1978, Pro-Dex is headquartered in Irvine, California, and serves customers in the United States and international markets.

Further Reading

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.